To summarize so far, we have demonstrated that disinhibition is an important feature of substance use disorders that may occur pre-morbidly to and serve as a risk-factor for the development of those disorders. Furthermore, various environmental and psychological variables are known to produce transient changes in disinhibition, and this fluctuating disinhibition may exert a causal influence on craving and substance consumption in the laboratory. From the clinical perspective, how can we exploit this knowledge in order to develop novel treatments for substance use disorders?
